FTSE MIB
25.892,18 -590,03 (-2,23%) Dow Jones
32.237,53 +132,28 (+0,41%) Nasdaq
11.823,96 +36,56 (+0,31%) Nikkei 225
27.385,25 -34,36 (-0,13%) Petrolio
69,20 -0,76 (-1,09%) Bitcoin EUR
25.592,06 -56,77 (-0,22%)
Evotec SE (0IRF.L)
| Chiusura precedente | 25,44 |
| Aperto | 25,15 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 25,12 - 25,74 |
| Intervallo di 52 settimane | 25,12 - 25,74 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,02 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemiaiPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluationT1D preclinical models with iPSC derived islet clusters transplanted in Sernova’s Cell Pouch has now demonstrated co
- GlobeNewswire
Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share
LONDON, Ontario, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/ XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that it has completed the second and final tranche of its previously announced private placement with Evotec SE (FSE:EVT) (NASDAQ: EVO) of 2,709,800 common shares of the Company (“Common Shares”) at a price of $2.50 per share for total proceeds of $6,774,500. Upon completion of the second tranch
- GlobeNewswire
Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes
Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin-Producing Beta CellsPartners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent DiabetesEvotec to Make Strategic Equity Investment of CAD $27 M / €20 M in SernovaSernova / Evotec Joint Conference Call and Webcast at 8:30 am EDT May 17, 2022 LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/X
